Regeneron Pharmaceuticals | REGN - Selling And Administration Expenses


Regeneron Pharmaceuticals reported $647.7M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
AbbVie USD 3.58B 316M Mar/2026
Agenus USD 10.56M 13.04M Dec/2025
Agios Pharmaceuticals USD 38.46M 4.51M Mar/2026
Alnylam Pharmaceuticals USD 282.51M 2.55M Mar/2026
Amgen USD 1.58B 354M Mar/2026
Astellas Pharma JPY 234.7B 12.92B Mar/2026
AstraZeneca USD 5.06B 455M Mar/2026
Biogen USD 554.3M 128.2M Mar/2026
BioMarin Pharmaceutical USD 258.28M 63.92M Mar/2026
Bristol-Myers Squibb USD 1.62B 564M Mar/2026
Eli Lilly USD 2.93B 198M Mar/2026
Gilead Sciences USD 1.45B 326M Mar/2026
GlaxoSmithKline GBP 2.12B 558M Mar/2026
Incyte USD 328.1M 62.31M Mar/2026
Ionis Pharmaceuticals USD 151M 21M Mar/2026
J&J USD 6.03B 719M Mar/2026
Kyowa Hakko Kirin JPY 41.07B 2.82B Mar/2026
Merck USD 2.67B 180M Mar/2026
Moderna USD 173M 135M Mar/2026
Neurocrine Biosciences USD 318.5M 16.7M Mar/2026
Novartis USD 3.14B 296M Mar/2026
Novartis USD 3.14B 296M Mar/2026
Pfizer USD 2.92B 1.16B Mar/2026
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Regeneron Pharmaceuticals USD 647.7M 127.3M Mar/2026
Roche Holding CHF 7.28B 3.99B Dec/2025
Sanofi EUR 2.49B 252M Mar/2026
Sarepta Therapeutics USD 54.03M 51.35M Mar/2026
Teva Pharmaceutical Industries USD 1000M 120M Mar/2026
Ultragenyx Pharmaceutical USD 88M 1000K Mar/2026
United Therapeutics USD 156.6M 34M Mar/2026
Vertex Pharmaceuticals USD 493.7M 6.7M Mar/2026